Latigo Biotherapeutics Inc. Company Profile
NASDAQ: LTGOHealth CareBiotechnology: Pharmaceutical PreparationsUSD
Market open · Delayed 15 min · as of Oct 8, 1:53 PM ET
Latigo Biotherapeutics at a glance
Latigo Biotherapeutics Inc. (NASDAQ: LTGO) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in Thousand Oaks, CA. Latigo Biotherapeutics is led by Mr. Nima Farzan M.B.A. and employs about 66 people. The company's shares have traded publicly since 2026.
At a market capitalization of $1.03 billion, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0002056611, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Latigo Biotherapeutics do?
Latigo Biotherapeutics, Inc. develops non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. The company's pipeline includes LTG-001, an oral NaV1.8 inhibitor designed to provide fast-acting, opioid-sparing relief for the treatment of acute pain; LTG-321, a NaV1.8 inhibitor candidate developed for the treatment of chronic musculoskeletal pain, starting with osteoarthritis; and LTG-418, a NaV1.8 inhibitor developed for the treatment of acute and chronic pain. Latigo Biotherapeutics, Inc. was formerly known as WVB-Desmond, Inc. and changed its name to Latigo Biotherapeutics, Inc. in March 2019. Latigo Biotherapeutics, Inc. was incorporated in 2018 and is based in Thousand Oaks, California.
Business description based on the company's public filings.
Company information
- Legal name
- Latigo Biotherapeutics Inc.
- Ticker
- NASDAQ: LTGO
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Nima Farzan M.B.A.
- Employees
- 66
- Headquarters
- 1300 Rancho Conejo Boulevard, Thousand Oaks, CA, United States
- Phone
- 805 716 2927
- Website
- latigobio.com
- IPO year
- 2026
- Market cap
- $1.03B
- SEC CIK
- 0002056611
Companies similar to Latigo Biotherapeutics
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| OPKOPKO Health Inc. | 1.38 | -0.55% | $1.03B | vs LTGO |
| SVRASavara Inc. | 4.81 | -1.54% | $987.24M | vs LTGO |
| AVLNAvalyn Pharma Inc. | 24.46 | -4.19% | $1.08B | vs LTGO |
| AKTSAktis Oncology Inc. | 17.50 | -2.78% | $973.34M | vs LTGO |
| SPTXSeaport Therapeutics Inc. | 17.91 | -0.14% | $958.46M | vs LTGO |
| MNKDMannKind Corporation | 3.43 | -0.72% | $1.10B | vs LTGO |
| LBRXLB Pharmaceuticals Inc | 34.37 | +0.62% | $1.11B | vs LTGO |
| AMPHAmphastar Pharmaceuticals Inc. | 26.07 | +2.08% | $1.11B | vs LTGO |